Pharma distribution & delivery in India, explained

What is pharma distribution and delivery?

Medicines travel a long way before they reach a patient. A manufacturer sells to a stockist, the stockist sells to a wholesaler, and the wholesaler sells to a chemist, who sells to the patient. Each step adds a small margin. This is called the distribution chain.

Startups in this area try to shorten or digitise that chain. Some are online pharmacies, where the patient uploads a prescription and gets medicines delivered. Others sell to chemists, helping small shops order stock through an app.

PharmEasy is the best-known online pharmacy in StopDown's data, and API Holdings is its parent company. They show how a consumer app and a trade business can sit inside the same group.

A few terms help when reading news about this area. MRP is the maximum retail price printed on a pack. A stockist holds medicines for a region, and a wholesaler supplies chemists. Generic medicines are copies of drugs whose patents have ended, sold at lower prices. A chronic refill is a repeat order for a long-term condition. Cold chain means keeping products at controlled temperatures. When a funding story mentions a pharmacy parent company, it usually means a holding company that owns several linked businesses such as the app, a wholesale arm and labs.

How did it grow in India?

India has hundreds of thousands of independent chemists. Many are small, run by a family and ordering from local wholesalers. Stock gaps, old pricing and paper bills were common, so there was room for software and better logistics.

Online pharmacies appeared in the mid-2010s and grew fast during the 2020 lockdowns, when people could not visit shops. Delivery companies and quick-commerce firms also began to carry basic health products.

Growth came with heavy discounts, and those discounts weighed on profit. Since then, firms have focused on better margins through chronic-care refills, private-label products and tighter delivery. Generic medicine stores, including the government's Jan Aushadhi outlets, add price pressure from another direction.

How do these businesses make money?

An online pharmacy earns the gap between what it pays a wholesaler or manufacturer and what the patient pays. In India the maximum retail price, or MRP, is printed on the pack, so the seller cannot charge more. Margins are therefore thin, and discounts cut into them further.

To improve earnings, companies push repeat orders, such as monthly refills for diabetes and blood pressure, which cost less to serve. They also sell own-brand generics that carry a higher margin, add lab tests and consultations, and sell advertising space to manufacturers.

B2B distribution platforms earn a trade margin or a small fee for each order they route to chemists. Their pitch is to reduce the stock chemists must carry and to give faster supply. Delivery services also earn a fee for fast or scheduled delivery.

One more point is worth knowing. Medicines are a trust product, so a patient who has a good first delivery tends to come back, while one bad experience with a wrong or late pack can lose that customer for good. This is why many companies invest in packaging, pharmacist checks and clear order tracking, even though these steps add cost to a business that already earns little on each pack.

What rules apply?

Selling medicines in India needs a drug licence from the state drug controller under the Drugs and Cosmetics Act, 1940, and a registered pharmacist must supervise dispensing. Prescription-only drugs need a valid prescription.

Online selling has no final rulebook. A draft e-pharmacy rule was published in 2018 and, as of October 2026, has not been finalised, according to the sources checked. In practice, platforms work with licensed pharmacies, and court cases and state actions have at times challenged online sales. Founders should follow any new notification closely.

The National Pharmaceutical Pricing Authority controls the ceiling prices of drugs on the National List of Essential Medicines, so sellers cannot charge above those prices. Patient data is covered by the Digital Personal Data Protection Act, 2023, whose Rules are being phased in. This is general information, not legal advice.

Who are the customers?

Patients are the end customers, and people with long-term conditions are the most valuable, because they order the same medicines every month. Older adults and people in small towns with few chemists benefit from delivery.

Chemists are customers of the B2B platforms, which help them order stock, check prices and reduce unsold goods. Hospitals and clinics also buy medicines in bulk through distributors.

Manufacturers are customers too, as they pay to reach chemists, run promotions and understand which products sell where.

How should you judge one, and what are the risks?

Look at the margin left after discounts, delivery and returns. Growth built on deep discounts can disappear when the discounts end.

Check how much of the business is repeat orders and how much comes from own-brand products. Both improve earnings. Also check the quality system: where stock is stored, how expiry is tracked and how the company handles recalls.

Finally, look at the legal base. Which licences does the company hold, and does it depend on partner pharmacies that could change terms? With no final e-pharmacy rule, this question matters.

The first risk is regulatory. A court order or a final e-pharmacy rule could change how online sellers must work. The second is margin: with a fixed MRP and constant discounting, profit per order is small.

A third risk is safety. A fake or expired medicine, or a dispensing error, can cause serious harm and damages trust at once. Cold-chain products need proper storage, and delivery partners must handle them correctly.

Things to watch include the e-pharmacy rule, the growth of chronic-care refills, tie-ups between pharmacies and diagnostic firms, and how quick-commerce players handle medicines. Group structures such as API Holdings, which has housed more than one business, show how companies combine pharmacy, distribution and diagnostics to share costs.

The breakdown

Business models

The numbers that matter

• Gross margin per order after discounts.
• Average order value and the share that are refills.
• Delivery cost per order and delivery time.
• Stock turnover: how fast inventory sells before expiry.
• Share of private-label sales in the mix.

Rules and regulators

Risks

• Unclear online-sale rules and possible court or regulator action.
• Thin margins with a fixed MRP and discounting.
• Safety and quality failures such as fake or expired stock.
• Opposition and price competition from offline chemists.
• Cold-chain and delivery handling costs.

Pharma distribution & delivery: latest on StopDown

• PharmEasy parent clears debt, weighs IPO return 5 October 2026
• Linux Laboratories raises $70 million from ChrysCapital 3 October 2026
• Netmeds revenue flat at ₹45 crore in FY26 30 September 2026
• Zenex buys SAVAVET pet care business 30 September 2026
• Rio Health raises Rs 43 cr in pre-series A funding 23 September 2026
• Practo reshuffles top leadership to drive global expansion 17 September 2026
• Wellness Forever Medicare files for initial public offering 12 September 2026
• Graph AI raises $13.3M for US and Europe expansion 10 September 2026

Every Pharma distribution & delivery story →

Most active investors here

1. All In Capital (2 rounds)
2. Better Capital (2 rounds)
3. 100Unicorns (1 round)
4. Accel (1 round)
5. AJVC Fund (1 round)
6. Amplify Partner (1 round)
7. Ashish Kacholia (1 round)
8. Avinya Fund (1 round)

Rounds StopDown covered in the last 12 months. Activity is not a measure of quality.

More in Healthcare & Life Sciences

• The healthcare sector in India, explained
• Telemedicine & primary care
• Diagnostics & AI-assisted care
• Mental health & wellness
• Biotech & medical devices